Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | USP19 | O94966 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1664984 | 0.82 | BRD4 (0.49) | BRD4FYNL3MBTL1KMT2A | |
| SCHEMBL23114507 | 0.78 | CHRM2 (0.33) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16058256 | 0.77 | L3MBTL1 (0.36) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23103442 | 0.77 | BRD4 (0.46) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL24493463 | 0.77 | BRD4 (0.46) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL26719202 | 0.75 | NOS3 (0.35) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL23710879 | 0.72 | MAPT (0.42) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3046934 | 0.72 | BRD4 (0.35) | BRD4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL2338238 | 0.71 | ACHE (0.38) | — | |
| SCHEMBL1618413 | 0.71 | OPRM1 (0.33) | BRD4CHRM2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | claimed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | claimed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | claimed |
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | UCB PHARMA, S.A. (BE) | 2010-09-02 | — | — | US | disclosed |
| EP-2152262-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB Pharma, S.A. (BE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008132142-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132139-A2 | NEW HETEROCYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | UCB PHARMA S.A. (BE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222326-A1 | New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders | CNR2, CNR1, SLC18A2 | BRD4 676/4885CHRM2 173/4885CHRM4 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.